CannLabs Inc (CANL)
0.00
USD |
OTCM |
Jun 21, 16:00
CannLabs Max Drawdown (5Y): 99.97% for May 31, 2024
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| May 31, 2024 | 99.97% |
| April 30, 2024 | 99.97% |
| March 31, 2024 | 99.97% |
| February 29, 2024 | 99.97% |
| January 31, 2024 | 99.97% |
| December 31, 2023 | 99.97% |
| November 30, 2023 | 99.12% |
| October 31, 2023 | 99.12% |
| September 30, 2023 | 99.12% |
| August 31, 2023 | 98.88% |
| July 31, 2023 | 98.88% |
| June 30, 2023 | 98.88% |
| May 31, 2023 | 98.88% |
| April 30, 2023 | 98.88% |
| March 31, 2023 | 98.88% |
| February 28, 2023 | 98.88% |
| January 31, 2023 | 98.88% |
| December 31, 2022 | 98.88% |
| November 30, 2022 | 98.88% |
| October 31, 2022 | 98.88% |
| September 30, 2022 | 98.78% |
| August 31, 2022 | 98.78% |
| July 31, 2022 | 98.78% |
| June 30, 2022 | 98.31% |
| May 31, 2022 | 98.24% |
| Date | Value |
|---|---|
| April 30, 2022 | 97.97% |
| March 31, 2022 | 97.97% |
| February 28, 2022 | 97.95% |
| January 31, 2022 | 97.81% |
| December 31, 2021 | 97.81% |
| November 30, 2021 | 97.81% |
| October 31, 2021 | 97.81% |
| September 30, 2021 | 97.81% |
| August 31, 2021 | 97.81% |
| July 31, 2021 | 97.81% |
| June 30, 2021 | 97.81% |
| May 31, 2021 | 97.81% |
| April 30, 2021 | 97.81% |
| March 31, 2021 | 97.81% |
| February 28, 2021 | 97.81% |
| January 31, 2021 | 97.81% |
| December 31, 2020 | 97.81% |
| November 30, 2020 | 97.81% |
| October 31, 2020 | 97.81% |
| September 30, 2020 | 97.64% |
| August 31, 2020 | 97.64% |
| July 31, 2020 | 97.64% |
| June 30, 2020 | 97.64% |
| May 31, 2020 | 97.64% |
| April 30, 2020 | 97.64% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
96.64%
Minimum
Jun 2019
99.97%
Maximum
Dec 2023
98.24%
Average
97.81%
Median
Oct 2020
Max Drawdown (5Y) Benchmarks
| AIM ImmunoTech Inc | 99.76% |
| Perspective Therapeutics Inc | 91.70% |
| Protalix BioTherapeutics Inc | 94.35% |
| Electromed Inc | 55.84% |
| Armata Pharmaceuticals Inc | 99.87% |